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Deregulated polyamine biosynthesis is emerging as a common feature of neuroblastoma and drugs targeting this metabolic
pathway such as DFMO are in clinical and preclinical development. The polyamine analog verlindamycin inhibits the polyamine
biosynthesis pathway enzymes SMOX and PAOX, as well as the histone demethylase LSD1. Based on our previous research in acute
myeloid leukemia (AML), we reasoned verlindamycin may also unblock neuroblastoma differentiation when combined with all-
trans-retinoic acid (ATRA). Indeed, co-treatment with verlindamycin and ATRA strongly induced differentiation regardless of MYCN
status, but in MYCN-expressing cells, protein levels were strongly diminished. This process was not transcriptionally regulated but
was due to increased degradation of MYCN protein, at least in part via ubiquitin-independent, proteasome-dependent destruction.
Here we report that verlindamycin effectively induces the expression of functional tumor suppressor—antizyme via ribosomal
frameshifting. Consistent with previous results describing the function of antizyme, we found that verlindamycin treatment led to
the selective targeting of ornithine decarboxylase (the rate-limiting enzyme for polyamine biosynthesis) as well as key oncoproteins,
such as cyclin D and Aurora A kinase. Retinoid-based multimodal differentiation therapy is one of the few interventions that extends
relapse-free survival in MYCN-associated high-risk neuroblastoma and these results point toward the potential use of verlindamycin
in this regimen.
Cancer Gene Therapy; https://doi.org/10.1038/s41417-021-00386-6
INTRODUCTION
Neuroblastoma is the most common extra-cranial solid tumor in
children. Half of the patients are diagnosed with high-risk
disease, which requires multi-modal therapy including che-
motherapy, surgery, and radiotherapy [1]. Despite intensive
treatment, 5-year survival rate for this group of patients remains
around 40%.
The two most important markers of poor survival probability in
neuroblastoma are undifferentiated tumor morphology and MYC
pathway activity [2]. Induction of differentiation is therefore one of
the most promising approaches to treat neuroblastoma, with
retinoic acid (RA) used in the clinic for patients with minimal
residual disease [3]. However, many patients relapse while on
retinoid treatment, which may suggest either gain of resistance or
selection (and expansion) of a resistant clone. MYCN amplification,
found in approximately 20% of neuroblastoma patients, indicates
particularly bad prognosis [4]. MYCN transcription factor belongs
to the MYC family and is involved in cell proliferation, growth,
apoptosis and differentiation. Its expression is restricted mainly to
embryonic development, which makes it a potentially good drug
target [5]. However, so far direct MYCN inhibition (i.e., inhibition of
MYCN binding to Max) has been rather challenging with no drugs
available at the moment. MYCN is therefore considered to be
undruggable due to reasons such as its nuclear localization and
lack of a defined ligand-binding site [6, 7].
One way of indirect MYC targeting is via polyamine depletion
[8, 9]. Polyamines are organic cations affecting numerous
processes in tumorigenesis, such as cell proliferation, tumor
growth, apoptosis, and angiogenesis [10]. There is a strong
relationship between MYC and polyamine levels; one of the
MYC target genes is ornithine decarboxylase (ODC1), a key
enzyme in polyamine biosynthesis. Treatment with an ODC1
inhibitor—α-difluoromethylornithine (DFMO)—has been shown
to decrease MYC levels [8]. DFMO is currently in phase II clinical
trial for neuroblastoma patients in remission (NCT02395666,
NCT01586260).
Besides inhibition of ODC1, polyamine synthesis can be also
targeted via the use of polyamine analogs. One such compound
is verlindamycin—a dual biguanide polyamine analog and LSD1
inhibitor (due to considerable homology between LSD1 and
polyamine oxidases) [11]. Verlindamycin (also called compound
2d) was shown to inhibit growth of acute myeloid leukemia
(AML) and estrogen-negative breast cancer in vitro [12, 13]. We
previously demonstrated that LSD1 inhibition reactivates RA-
induced differentiation in leukemia, which made us hypothesize
that combination of verlindamycin and all-trans-retinoic acid
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(ATRA) can also be effective in neuroblastoma [14]. LSD1 is
strongly upregulated in poorly differentiated neuroblastoma
and its inhibition was shown to inhibit neuroblastoma growth
both in vitro and in vivo [15]. In addition, polyamine depletion
has been shown to induce differentiation in a mouse neuro-
blastoma cell line [16]. We therefore studied the impact of
verlindamycin on neuroblastoma cells to show that this
compound decreases proliferation rate and MYCN expression,
whereas enhances cell differentiation in combination with ATRA.
Taken together, we propose a novel mode of action of
verlindamycin via upregulation of antizyme, a negative reg-
ulator of polyamine pathway.
MATERIALS AND METHODS
Compounds and cell culture
2d, 1,15–bis{N5–[3,3–(diphenyl)propyl]–N1–biguanido}–4,12–diazapentadecane,
verlindamycin was generously provided by Dr Patrick Woster from Medical
University of South Carolina; 10 mM stock in dimethyl sulfoxide (DMSO)
was stored at −20 °C. ATRA (Sigma) was stored as a 10mM stock in DMSO
and ethanol (50/50) at −80 °C; GSK-LSD1 (Sigma) was stored at −20 °C as
1mM stock solution in DMSO; DFMO (Enzo Life Sciences) was stored at
−20 °C as 1 M solution dissolved in sterile water. Neuroblastoma cell lines
were obtained from German Collection of Microorganisms and Cell
Cultures (Kelly, SH-SY5Y), Public Health Collection (SK-N-BE(2)-C), American
Type Cell Collection (SK-N-AS, IMR32, HEK-293T), and were all short tandem
repeat-profiled. SHEP-Tet21/N were a gift from Dr Deborah Tweddle
(Newcastle, UK). Cells were grown in RPMI-1640 medium (Sigma)
supplemented with 10% fetal bovine serum (FBS; Gibco) without addition
of antibiotics except for HEK-293T, which were grown in Dulbecco’s
Modified Eagle Medium with 10% FBS and 1% PenStrep. Cells were
cultured in standard conditions (5% CO2 and 37 °C) and routinely tested for
Mycoplasma species (Sigma MP0035, LookOut® Mycoplasma PCR Detec-
tion Kit). For three-dimensional (3D) sphere culture, 2500 cells per well
were seeded in ultra-low attachment round bottom plate (Costar, 7007)
and imaged with Celigo to monitor growth. To establish 50% growth-
inhibitory concentration (GI50) for verlindamycin, cells were grown in 96-
well plates for 96 h and then treated with a range of concentrations. After
72 h of compound exposure, cells were fixed and cell viability was assessed
with the use of sulforhodamine B assay [17]. GI50 was calculated with the
use of GraphPad Prism.
Cell proliferation assay and clonogenic assay
To assess difference in proliferation rate, cells were seeded in two black
96-well plates. Twenty-four hours after seeding, compounds were added to
plates. The first plate was read as a reference after 24 h using CellTiter-Glo
(Promega), according to the manufacturer’s protocol, on Synergy 2
Microplate Reader (BioTek). The second plate was read in the same way
after 6 days of incubation. For clonogenic assay, cells were treated with
compounds for 10 days after which they were seeded into 6-well plates,
1000 live cells per well. After 2 weeks of culture, cells were fixed with 4%
paraformaldehyde and stained with crystal violet solution (Sigma).
Colonies were counted with Oxford Optronics Gelcount.
Annexin V flow cytometry assay
FITC annexin V apoptosis detection kit (BD Pharmingen) was used to assess
apoptosis in cells treated with compounds for 6 days, according to the
manufacturer’s protocol.
Western blotting
Cells were lysed directly in LDS sample buffer with reducing agent
(Invitrogen); samples were sonicated and denatured by 5min incubation at
95 °C. Equal amount of protein was loaded on a gel and run at 130 V, then
transferred to polyvinylidene difluoride membrane. Next, the membrane
was blocked with 5% milk and incubated with primary antibody (Santa
Cruz: MYCN Sc53993; Cell Signaling: glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) 2118L, Aurora A 4718, Cyclin D1 2922; Abcam: ODC1
ab97395, LSD1 ab17721) at 1:1000 for 2 h at room temperature. After
washing, the membrane was incubated with secondary antibody
conjugated with horseradish peroxidase (Dako) at 1:10,000 and washed
again, and the reaction was developed with Lumigen ECL reagents
(Lumigen) and imaged on LAS-3000 Imaging System (Fujifilm).
Protein stability assays
For proteasomal inhibition, cells treated with verlindamycin for 4 days
were treated with 10 μM MG-132 (Sigma) for 16 h. To assess MYCN half-life
in cells treated with verlindamycin, cells were exposed to 25 μg/ml
cycloheximide for up to 2 h. Cells were harvested, and after performing
western blotting, band intensity was quantified with ImageJ.
Immunofluorescence and proximity ligation assay (PLA)
Cells were grown on coverslips, treated with compounds, and fixed with
4% paraformaldehyde on day 6. Next, they were permeabilized with 0.2%
Triton X-100 in phosphate-buffered saline (PBS), washed, and blocked for
30min in immunofluorescence buffer (IFF; 1% bovine serum albumin, 2%
FBS in PBS). Cells were then incubated with primary antibody (Santa Cruz:
MYCN Sc53993 1:5000; Cell Signaling: Neurofilament-l 2837S 1:100) for 1 h
at room temperature. After washing, cells were incubated with secondary
antibody (goat anti-rabbit Alexa-Fluor 568 and goat anti-mouse Alexa-
Fluor 488, Invitrogen) diluted 1:5000 in IFF for 1 h. Finally, they were
washed with PBS (last wash with 1:5000 4,6-diamidino-2-phenylindole) and
nanopure water and mounted in Fluoromount-G (SouthernBiotech).
Fluorescence was observed with Zeiss confocal microscope, with the use
of ZEN software. DuoLink PLA was performed according to the
manufacturer’s protocol (Sigma); fluorescence was registered with Zeiss
confocal microscope and scored with the DuoLink ImageTool software.
RNA extraction, reverse transcription, and quantitative PCR
(qPCR)
To analyze gene expression, cells were harvested at 70% confluency and
total RNA was isolated (Zymo Research); 500 ng of RNA was used for
reverse transcription (qScript, Quantas). For SYBR qPCR, 5 ng of cDNA was
mixed with primers (RARB Fwd TGAGTCCTGGGCAAATCCTG Rev
CGGTTTGGGTCAATCCACTGA, CRABP2 Fwd TCGGAAAACTTCGAGGAATTGC
Rev CCTGTTTGATCTCCACTGCTG, TrkB Fwd TGTTCAGCACATCAAGCGACA
Rev CAAAGGCTCCTTCGCCTAGC, Ret Fwd GGCATCAACGTCCAGTACAAG
Rev TGAGGTGACCACCCCTAGC, GAPDH Fwd ATGGGGAAGGTGAAGGTCG
Rev TAAAAGCAGCCCTGGTGACC), master mix (SYBR Green PCR Master
Mix), and water. For TaqMan qPCR, 5 ng of cDNA was mixed with Applied
Biosystems probes (MYCN Hs00232074_m1, OAZ1 Hs00427923_m1, GAPDH
4310884E), master mix (Gene Expression Master Mix, Life Technologies),
and water. qPCR reaction was performed as follows: 50 °C for 2 min, 95 °C
for 10min, (95 °C for 15 s, 60 °C for 1 min) × 40 cycles on StepOnePlus Real-
Time PCR Systems (Life technologies) with melt curve analysis for SYBR.
Gene expression was normalized to GAPDH with comparative Ct method.
Small interfering RNA (siRNA) transfection
siRNA targeting OAZ1 and LSD1 and non-targeting was prepared according
to the manufacturer’s protocol (siGENOME SMART Pool, Dharmacon).
Briefly, siRNAs and DharmaFECT (Dharmacon; 0.1% (v/v) of final volume)
were added to separate tubes with serum-free media and incubated for
5min at room temperature. After that, DharmaFECT was distributed
between tubes with siRNAs and tubes were incubated at room temperature
for 20min. Afterwards, complete media (with or without verlindamycin)
was added to tubes and distributed to each well. Knockdowns were
observed after 96 h (and cells were re-treated after 72 h according to the
same protocol where indicated).
Expression microarray
To study the effect of combined treatment with verlindamycin and ATRA
on gene expression in neuroblastoma cell lines, SK-N-BE(2)-C and SK-N-AS
were treated with a combination of verlindamycin (1.75 μM= 0.5× GI50)
and ATRA (1 μM). Cells were treated on day 0, re-treated on day 3, and
harvested on day 6. RNA was extracted and sent to Oxford Gene
Technology in Oxford to perform the Agilent expression microarrays and
analysis. Genes with a false discovery rate (FDR) of 0.05 were selected as
representing significant differential expression and the list was further
filtered to include those where the logFC was either >1 or <−1. Expression
of genes with logFC values between groups outside the range −1.5 to
+1.5 (a subset of the most strongly differentially expressed genes) was
then visualized as heatmaps. We also used the pathway commons 2
database to annotate differentially expressed genes with known regulatory
relationships (“controls-expression-of”) to show networks of upregulated
and downregulated nodes with edges representing regulatory relation-
ships with the differentially expressed regulatory genes (nodes). Raw data,















final, normalized results as well as microarray metadata has been
deposited in NCBI’s gene expression omnibus as series GSE178900.
Frameshifting assay
The assay was performed in HEK293T cell line; therefore, first verlindamy-
cin GI50 was established in HEK293T. Cells were seeded in 96-well plates
and treated with a range of compound concentrations. After 48 h of
compound exposure, cell viability was assessed with CellTitre-Blue on
Promega GloMax Discover plate reader. We received four plasmids from
Dr John F. Atkins: Oaz1 wild type, oaz1 in frame control, oaz2 wild type,
and oaz2 in frame control in a pSGCluc plasmid vector containing a dual
luciferase reporter system (Loughran et al. [18]). Luciferase activity was
observed in wild-type plasmids if frameshifting occurred, whereas in the
control plasmids, no frameshifting was needed as a thymine nucleotide is
missing from the DNA sequence coding for antizyme 1 and 2. For the
frameshifting assay, HEK293T cells were seeded into white 96-well plates at
a density of 20,000 cells/well with the addition of 2.5 mM DFMO. After 24 h,
cells were transfected with 0.2 ng of plasmids with the use of
Lipofectamine (Invitrogen). After 6 h transfection, solutions were removed
and cells were treated with compounds (verlindamycin and spermidine) at
an indicated concentration for 48 h. Afterwards, Dual-Glo Stop & Glo
Luciferase Assay System (Promega) was used to analyze Firefly and Renilla
luciferase activities and the luminescence was measured on GloMax
Discover plate reader. Percentage frameshifting (%FS) activity was
determined by obtaining firefly:renilla luciferase ratios, then dividing
reporter values by in-frame control values. Relative FS was calculated by
the following method: background %FS activity determined from the
2.5 mM DFMO control was subtracted from the %FS activity for the treated
samples. The background-corrected %FS activity of each compound was
then divided by the background-corrected %FS activity induced by 25mM
spermidine and multiplied by 100.
RESULTS
Verlindamycin inhibits neuroblastoma cell proliferation and
enhances the growth-inhibitory effect of ATRA
In order to analyze the effects of verlindamycin (Fig. 1A), we first
performed dose–response assays in a panel of neuroblastoma cell
lines. Verlindamycin inhibited growth in all neuroblastoma cell
lines tested with GI50 values in the micromolar range (Fig. 1B and
Supplementary Fig. 1). MYCN-amplified cells were more sensitive
to the compound compared with non MYCN-amplified cells, but
the difference was not statistically significant. Next, we tested
verlindamycin efficiency on tumor spheroids—neuroblastoma
cells grown in 3D—as this type of cell culture provides a better
representation of tumor physiology than cells grown in mono-
layer. We found that verlindamycin treatment decreased growth
of tumor spheroids (as measured by spheroid diameter change,
which was from −4 for 10 μM to +363 μm for control in Kelly and
from −123 μm for 10 μM to +241 μm for control in SK-N-BE(2)-C)
with GI50 values similar to those obtained with adherent cells
(3.35 μM in two-dimensional (2D) versus 4.7 μM in 3D for SK-N-BE
(2)-C and 3.5 μM in 2D versus 1.58 μM in 3D for Kelly) (Fig. 1C).
Treatment with either verlindamycin or ATRA alone for 6 days
decreased the proliferation rate of neuroblastoma cells; however,
the combined treatment had the strongest antiproliferative effect
leaving only 2–15% of cells metabolically active (Fig. 1D).
Because the treatment with ATRA and verlindamycin left very
few metabolically active cells, we hypothesized that it may induce
cell death. To test this hypothesis, cells were stained with annexin
V (Supplementary Fig. 2), which revealed that verlindamycin and
ATRA treatment increases percentage of cells both in early and
late apoptosis (SK-N-BE(2)-C: 16% of apoptotic cells in control
versus 50% in treated; Kelly: 7 versus 82%; SKNAS: 7 versus 41%).
To address the question whether cells that survive verlindamycin
and ATRA treatment would be able to grow at low cell density, we
performed a clonogenic assay. Cells treated with verlindamycin
and ATRA for 10 days (alongside controls) were seeded at 1000
cells per well and cultured for 2 weeks. Cells treated with
verlindamycin and ATRA were not only forming significantly less
colonies, if any, but the colonies were also smaller (Fig. 1E). Thus,
treatment with the combination of verlindamycin and ATRA leads
to decrease in cell proliferation and induction of cell death in both
2D and 3D cultures.
Verlindamycin enhances RA-induced differentiation in
neuroblastoma
After establishing that verlindamycin has an antiproliferative effect
on its own and that it enhances the growth-inhibitory effect of
ATRA, we investigated whether its cytostatic effect may be caused
by cell differentiation. After 6 days of combined treatment, some
profound changes in cell morphology could be observed, with
cells elongating and extending neurites (Fig. 2A and Supplemen-
tary Fig. 3A). Staining with neurofilament-light, a well-established
neural marker, confirmed that the cell extensions observed by a
light microscope are neurites (Fig. 2B and Supplementary Fig. 3B).
In MYCN-amplified SK-N-BE(2)-C and Kelly, the intensity of staining
and the number of neurites were increased by both ATRA and
verlindamycin single treatments, with the strongest effect in the
combined treatment. Interestingly, the combined verlindamycin
and ATRA treatment led to a modest induction of neurites also in
the non-neuronal SK-N-AS. To confirm differentiated status of cells
treated with verlindamycin and ATRA, we assessed the expression
of a set of previously published RA-response genes: CRABP2 and
RARB, and neural markers: RET and TrkB [19]. Remarkably, markers’
levels in cells treated with combination of compounds were
higher than in cells treated with any of the agents alone, especially
inMYCN-amplified cells such as SK-N-BE(2)-C and Kelly (Fig. 2C and
Supplementary Fig. 3C). This indicates that there may be a
synergistic effect between verlindamycin and ATRA, possibly
down to the epigenetic role of verlindamycin. Overall, these
results indicate that addition of verlindamycin enhances the
differentiation-inducing properties of ATRA.
To assess the underlying effect of verlindamycin and ATRA
treatment on neuroblastoma cells, we performed transcriptomics
analysis of MYCN-amplified SK-N-BE(2)-C and non-MYCN-amplified
SK-N-AS. Expression microarrays were performed after 6 days of
treatment—on cells that had inhibited growth and were well
differentiated. In both cell lines, we noted that histograms of
adjusted p values (FDR) had non-uniform distributions that
included a sharp peak of very small adjusted p values, in contrast
to the uniform distribution of p values expected with random data
(Supplementary Fig. 4A, D). Differential gene expression analysis
between the ATRA plus verlindamycin-treated and vehicle-treated
SK-N-BE(2)-C cells identified 348 spots as significantly upregulated,
corresponding to 255 unique genes, and a further 539 significantly
downregulated spots, corresponding to 378 unique genes. In a
similar analysis of the SKNAS gene expression data set, a total of
952 spots showed increased expression corresponding to 661
unique genes, while 600 spots showed downregulation, corre-
sponding to 427 unique genes. Volcano plots revealed that a small
number of spots represented both highly significant and strongly
differentially expressed genes and they were not restricted to
either highly expressed or weakly expressed genes (Supplemen-
tary Fig. 4B, C, E, F). We next visualized the expression of a subset
of the most strongly differentially expressed genes in each group
as heatmaps (Supplementary Fig. 5). Supplementary Fig. 6 shows
networks of upregulated (yellow) and downregulated (cyan)
nodes with edges representing regulatory relationships with the
differentially expressed regulatory genes (gray nodes). Gene Set
Enrichment Analysis revealed downregulation of several onco-
genic pathways, such as mammalian target of rapamycin (mTOR),
phosphoinositide-3 kinase (PI3K)-Akt, and DNA repair (Fig. 3 and
Supplementary Fig. 7). Additionally, MYC targets were highly
upregulated in control compared to verlindamycin- and ATRA-
treated cells. Taken together, these results suggest that reduced
proliferation of cells treated with verlindamycin and ATRA may be
due to downregulation of several oncogenic pathways.
Z. Urban-Wójciuk et al.
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Verlindamycin downregulates the expression of MYCN
protein by targeting its stability
MYC targets pathway was prominently downregulated upon
verlindamycin and ATRA treatment (Fig. 3). MYCN is a major
determinant of outcome in neuroblastoma, amplified in the most
aggressive tumors. No direct MYCN inhibitor is currently available
while a lot of research interest is focused on the development of
therapeutics that target MYCN indirectly [20–22]. As MYCN-
amplified and MYCN-driven neuroblastoma cell lines were very
sensitive to the combination of verlindamycin and ATRA, we
investigated the effect of this combined treatment on MYCN itself.
We measured the expression of MYCN protein upon treatment
with increasing levels of verlindamycin and its combination with
ATRA. Expression of MYCN protein was affected by as little as
1.75 µM (0.5× GI50) of verlindamycin and the effect was even
stronger upon addition of ATRA (Fig. 4A and Supplementary Fig.
8A). Interestingly, expression of MYCN mRNA in SK-N-BE(2)-C and
Kelly cells treated with verlindamycin and ATRA for 6 days was not
downregulated (Fig. 4B and Supplementary Fig. 8B). Therefore, we
hypothesized that this treatment targets MYCN protein but not
the transcription of its mRNA. To test this hypothesis, we
examined the effect of verlindamycin on MYCN stability and
Fig. 1 Verlindamycin inhibits neuroblastoma cell proliferation and enhances growth-inhibitory effect of ATRA. A Structure of
verlindamycin. B Dose response by SRB assay for a panel of non MYCN-amplified (blue) and MYCN-amplified (red) neuroblastoma cell lines
treated with verlindamycin for 72 h. 50% growth-inhibitory (GI50) values are shown for individual cell lines (left panel) and non-MYCN-
amplified versus MYCN-amplified cell lines (right panel). C SK-N-BE(2)-C and Kelly cells cultured as tumor spheroids were treated with
verlindamycin for 72 h and changes in spheroid diameter were assessed using a Celigo S Imaging Cell Cytometer. D Viability assessment as
measured by CellTiter Glo (Promega) in SK-N-BE(2)-C and Kelly cells grown in monolayer. Metabolic activity of cells treated with 0.5× GI50
verlindamycin in combination with 1 μM ATRA was measured by CellTiter Glo after 6 days of treatment. E Cells treated with 0.5× GI50
verlindamycin and 1 μM ATRA for 10 days were tested for their ability to form colonies from single cells within 14 days. All the experiments
were performed in triplicates and a representative result or mean is shown. Student’s t test was performed to calculate statistical significance,
*p < 0.05, **p < 0.005, ***p < 0.0005, error bars show standard deviation.
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proteasomal degradation. Cells treated with verlindamycin were
exposed to cycloheximide (an inhibitor blocking protein synthesis)
for 2 h. We found that verlindamycin decreases ~2-fold MYCN half-
life (20 min for treated versus 50min for untreated in SK-N-BE(2)-C
and 25 versus 60min in Kelly) (Fig. 4C and Supplementary Fig. 8C).
We then tested whether MYCN protein levels are reduced
because of protein degradation by the proteasome. We found
that treatment with the proteasomal inhibitor MG-132 brings the
level of MYCN in verlindamycin-treated cells back to control level
(Fig. 4D and Supplementary Fig. 8D). We then performed PLA to
study the MYCN–Fbxw7 interaction in cells treated with verlinda-
mycin (Fig. 4E). FBXW7 ubiquitin ligase interacts with MYCN to
target it for proteasomal degradation, and as we expected, cells
treated with verlindamycin had significantly more FBXW7-MYCN
complexes. All these data suggest that verlindamycin down-
regulates the expression of MYCN by targeting its stability. To
further study the connection between MYCN levels and cell
differentiation, we also investigated the effect of direct MYCN
inhibition by siRNA on neuroblastoma cells. We found that MYCN
downregulation by siRNA leads to neuroblastoma differentiation
as measured by morphological changes and NF-L-expressing
neurite outgrowth (Supplementary Fig. 9), which may indicate that
differentiated cells should have lower MYCN levels.
Verlindamycin is not acting via inhibition of LSD1
Our results show that verlindamycin is a potent inhibitor of
neuroblastoma growth and an enhancer of ATRA-induced
differentiation. Because this compound is a dual LSD1 inhibitor
and polyamine analog, we decided to test whether it is acting via
inhibition of LSD1. We first tested GSK-LSD1, recently described as
a potent LSD1 inhibitor in small cell lung cancer [23]. We treated
neuroblastoma cells with a range of GSK-LSD1 concentrations with
or without the addition of ATRA (Fig. 5A and Supplementary Fig.
10). GSK-LSD1 had a modest growth-inhibitory effect and was not
amplified by ATRA. In addition, GSK-LSD1 did not downregulate
the expression of MYCN protein (Fig. 5B and Supplementary Fig.
10). To ensure that LSD1 inhibition is not the mechanism of action
of verlindamycin, we also tested a genetic blocker. Even though
Fig. 2 Verlindamycin enhances ATRA-induced differentiation in neuroblastoma. SK-N-BE(2)-C and SK-N-AS were treated with 0.5× GI50
verlindamycin and 1 μM ATRA for 6 days. A Brightfield microscopic pictures show morphological differences upon treatment. B Cells were
fixed and stained with neurofilament light chain (NFL, red) and DAPI (blue). C mRNA expression of ATRA-target gene (CRABP2) and neural
markers (RARB, RET) was measured by RT-qPCR and normalized to GAPDH. All the experiments were performed in triplicates and a
representative result or mean is shown; error bars show standard deviation.
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the siRNA-mediated knockdown of LSD1 (encoded by KDM1A
gene) was very efficient (protein level in Fig. 5C and RNA in
Fig. 5D), it did not lead to MYCN downregulation. Therefore, all the
evidences show that the growth-inhibitory and MYCN down-
regulating effect of verlindamycin is not due to LSD1 inhibition.
Verlindamycin induces upregulation of antizyme and leads to
downregulation of antizyme targets
It was reported that increase in polyamine levels leads to
downregulation of ODC1 as a feedback mechanism to regulate
and keep polyamine levels low [24]. This process is triggered by
antizyme—a protein that leads to ubiquitin-independent degrada-
tion of ODC1. The schematic showing the frameshifting of antizyme
upon polyamine induction is depicted in Fig. 6A. To assess whether
the increase in polyamine analog levels will also upregulate
functional antizyme levels, we performed frameshifting assay using
Dual Luciferase Reporter System (as previously described [18]). For
frameshifting assay, HEK293 cells were transfected with wild-type or
in-frame control plasmids for antizyme 1 and 2. Verlindamycin was
added on to cells alongside spermidine (as a positive control) and
the assay was read with the use of Dual-Glo Stop & Glo Luciferase
Assay System with the results shown in Fig. 6B. Even though the
cells were treated with verlindamycin for 24 h only, we already
observed a strong induction of antizyme at GI50 concentrations
(GI50 presented in Supplementary Fig. 1). These results indeed
indicate that verlindamycin induces antizyme frameshifting.
We then further assessed whether the induced antizyme was
able to downregulate its targets in neuroblastoma. Four-day
verlindamycin treatment led to significant ODC1 downregulation
(Fig. 7A) without affecting its transcription (Fig. 7B). Simulta-
neously, other known targets of antizyme—cyclin D1 and Aurora
A—were also downregulated at a protein level. In MYCN-amplified
cells (Kelly and SK-N-BE(2)-C), downregulation of Aurora A was
coupled with a decrease in MYCN level. At the same time, we also
showed that mRNA level of OAZ1 increased upon verlindamycin
treatment in all tested cell lines (Fig. 7C). Next, we performed
antizyme 1 (OAZ1) knockdown with siRNA. After 4 days of siRNA
treatment (with or without verlindamycin), mRNA levels of OAZ1
were measured alongside with antizyme targets (Fig. 7D, E). Even
though mRNA levels of OAZ1 were low upon combination of OAZ1
knockdown and verlindamycin, ODC1, Aurora A, and cyclin D
levels were at a level similar to verlindamycin-only treatment. This
may suggest that antizyme has a long half-life and therefore siRNA
knockdown cannot efficiently decrease protein levels or verlinda-
mycin is counteracting the knockdown effect.
Finally, we compared verlindamycin to DFMO (eflornithine), an
established ODC1 inhibitor. DFMO efficiently inhibited the growth
of SK-N-BE(2)-C (Fig. 8A) but had a modest impact on MYCN
expression (Fig. 8B). Additionally, 6-day treatment with DFMO did
not enhance ATRA-induced differentiation (Fig. 8C). Therefore,
DFMO did not recapitulate the effect of verlindamycin. All these
results suggest that verlindamycin has a unique ability to induce
Fig. 3 Gene Set Enrichment Analysis (GSEA) of differential gene expression in SK-N-BE(2)-C cells following co-treatment with
verlindamycin (2d) and ATRA. Gene expression data generated by expression microarray analysis following 6 days of co-treatment with 1 μM
ATRA and 0.5× Gi50 verlindamycin versus untreated (DMSO) control were analyzed using GSEA to extract biological knowledge and highly
significantly enriched gene sets are shown. The most upregulated genes in vehicle control are shown on the left side (red), while the most
upregulated genes following ATRA+ 2d treatment are shown on the right side (blue). Black bars represent the positions of the vehicle control
versus ATRA+ 2d upregulated signature genes in the ranked list. Green curves represent the evolution gene density. Normalized enrichment
scores (NES) reflect the degree to which genes are overrepresented. When the distribution is random, the enrichment score is zero.
Enrichment of signature genes at the top of the ranked list results in a large positive deviation of the NES from zero. q-value false discovery
rate (FDR)-adjusted q-value.
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Fig. 4 Verlindamycin downregulates the expression of MYCN protein in MYCN-amplified neuroblastoma. A MYCN protein levels were
assessed in SK-N-BE(2)-C cells treated for 6 days: with different concentrations of verlindamycin (upper panel; GI50= 3.5 μM) and with 0.5× GI50
verlindamycin combined with 1 μM ATRA (lower panel). B MYCN mRNA expression was measured by RT-qPCR (relative to GAPDH) in SK-N-BE
(2)-C cells treated for 6 days with 0.5× GI50 verlindamycin alone or combined with 1 μM ATRA. C SK-N-BE(2)-C cells pretreated with 0.5× GI50
verlindamycin for 4 days were exposed to 25 µg/ml cycloheximide for up to 2 h. D SK-N-BE(2)-C cells pretreated with verlindamycin for 4 days
were exposed to 10 µM MG-132 for 16 h. E PLA was performed on SK-N-BE(2)-C to assess MYCN-FBXW7 interaction; dots were quantified (left
panel). All the experiments were performed in triplicates and a representative result or mean is shown; error bars show standard deviation.
Student’s t test was performed to calculate statistical significance, *p < 0.05.
Fig. 5 Inhibition of KDM1A/LSD1 is not the mechanism of action of verlindamycin. A SK-N-BE(2)-C cells were treated with a range of GSK-
LSD1 concentrations combined with 1 μM ATRA for 6 days after which cell viability was assessed by CellTiter Glo. B MYCN expression level was
tested in cells treated with GSK-LSD1 with or without addition of 1 μM ATRA for 6 days. C SK-N-BE(2)-C and Kelly cells with siRNA-mediated
KDM1A knock-down (alongside non-targeting control) and treated with ATRA (for 6 days) were harvested to assess the expression of MYCN
and LSD1. D mRNA expression of KDM1A was also tested in SK-N-BE(2)-C and Kelly cells treated with ATRA and KDM1A-targeting siRNA;
expression measured by RT-qPCR relative to GAPDH. All the experiments were performed in triplicates and a representative result or mean is
shown; error bars show standard deviation.
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antizyme, which degrades ODC1, Aurora A, and Cyclin D1 leading
to reduced cell growth and MYCN expression.
DISCUSSION
In this study, we present a unique compound of dual potency—a
polyamine analog as well as a LSD1 inhibitor, combined with an
eminent differentiating agent—RA. We show that the addition of
verlindamycin increases ATRA-driven differentiation (in neuroblas-
toma cell lines), indicated with distinctive morphology and
expression of neural markers. RA has long been used as
differentiation-inducing agent in the treatment of neuroblastoma
and maximal morphological differentiation is usually reached after
6 days of RA exposure [25], which is a timepoint we used in this
study. In clinical practice, 13-cis RA is the form of RA given to
neuroblastoma patients as it has higher maximally tolerated dose
and longer half-life than ATRA. However, 13-cis RA is isomerized to
ATRA inside cells, which justified the use of ATRA in our in vitro
experiments [26].
The growth of cells treated with the combination of verlinda-
mycin and ATRA is almost completely inhibited and a big
proportion of the cells became apoptotic. Verlindamycin alone
induced apoptosis in Kelly cells, but to induce apoptosis in SK-N-
BE(2)-C, it had to be combined with ATRA. Although both those
cell lines are MYCN amplified, Kelly is derived from primary
neuroblastoma while SK-N-BE(2)-C from metastatic site (bone
marrow); therefore, more aggressive SK-N-BE(2)-C may be more
resistant to verlindamycin-induced apoptosis. However, the level
of differentiation induced by the combination of verlindamycin
and ATRA was similar.
The growth-inhibitory effect of verlindamycin may be caused
by polyamine depletion per se and/or by downregulation of
MYCN, an oncoprotein, which is the primary driver of prolifera-
tion in the high-risk neuroblastoma subset. We show that
verlindamycin is affecting MYCN stability and degradation but
has no impact on its transcription. The mechanism behind it may
be the upregulation of antizyme, a negative modulator of
polyamine biosynthesis. Polyamines play a crucial role in cell
growth and proliferation such that their levels have to be tightly
controlled. High intracellular polyamine levels induce a riboso-
mal frameshift, which leads to production of a full-length
antizyme protein [27]. Antizyme decreases polyamine levels in
three different ways: by disrupting ODC1 dimers, by targeting
ODC1 for degradation, and by inhibiting extracellular polyamine
uptake. It was shown before that polyamine analogs stimulate
cells for antizyme production and that antizyme levels correlate
with growth inhibition [28]. Interestingly, ODC1 is not the only
antizyme target, the other two being cell cycle regulatory protein
cyclin D1 and Aurora-A, a key factor in regulating MYCN stability
[29, 30]. Our results demonstrate increased antizyme frameshift-
ing as well as degradation of antizyme targets (ODC1, Aurora A,
Cyclin D1) upon treatment with verlindamycin. DFMO treatment
did not recapitulate the effect of verlindamycin possibly because
it has a different mode of action—through decreasing polyamine
levels via direct ODC1 inhibition [31].
To understand deeper the mechanism underlying the pro-
found effect of combined verlindamycin and ATRA treatment on
neuroblastoma cells, we performed transcriptomics analysis.
Even though MYCN mRNA was not downregulated by the
treatment in SK-N-BE(2)-C, MYC targets were among the most
strongly affected gene sets. This, however, was in line with our
finding that there is a decrease in MYCN protein level due to
increased MYCN degradation.
We have previously shown that PI3K/mTOR inhibitors kill MYCN-
amplified neuroblastoma cells and have the ability to eliminate
MYCN protein in vivo [32]. Verlindamycin appears to affect mTOR
and PI3K pathways in both MYCN-amplified SK-N-BE(2)-C and non-
MYCN-amplified SK-N-AS. Alterations in the PI3K pathway are
frequent in tumors and promote sustained growth and prolifera-
tion [33]. Although the interaction between PI3K-mTOR pathway
Fig. 6 Verlindamycin treatment induces frameshifting of antizymes 1 and 2. A Schematic showing polyamine-induced frameshifting of
antizyme. B Verlindamycin-induced frameshifting of antizymes 1 and 2 relative to 25 µM spermidine. Briefly, 293T cells were transfected with
antizyme 1 or 2 frameshifting reporters or in-frame controls with the addition of 25 µM spermidine or verlindamycin as indicated. Percentage
frameshifting (%FS) activity was determined with Dual-Glo (Promega) by obtaining firefly:renilla luciferase ratios, then dividing reporter values
by in-frame control values. The background-corrected %FS activity of each compound concentration was then divided by the background-
corrected %FS activity induced by 25mM spermidine and multiplied by 100. All the experiments were performed in triplicates and a
representative result is shown.
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Fig. 7 Functional analysis of verlindamycin-induced frameshifting of antizyme. A SK-N-BE(2)-C, Kelly, and SK-N-AS cells were treated with
0.5× GI50 verlindamycin for 4 days, after which the expression of Cyclin D1, Aurora A, and MYCN was measured. GAPDH expression is shown as
a loading control. At the same time, the expression of B ODC1 and C OAZ1 mRNA was measured by qPCR, shown relative to GAPDH. D, E After
96 h of siRNA knock-down of OAZ1 combined with verlindamycin treatment, D the expression of OAZ1 targets was measured by western
blotting. E Expression of OAZ1 mRNA was assessed by RT-qPCR (relative to GAPDH) in cells transfected with siRNA. All the experiments were
performed in triplicates and a representative result or mean is shown; error bars show standard deviation. Student’s t test was performed to
calculate statistical significance, *p < 0.05.
Fig. 8 DFMO affects neuroblastoma viability and MYCN expression but does not enhance differentiation-inducing potential of ATRA. SK-
N-BE(2)-C, Kelly, and SK-N-AS cells were treated with 5mM DFMO, a well-studied ODC1 inhibitor, combined with 1 μM ATRA for 6 days.
A Relative viability of those cells was measured by CellTiter Glo. B MYCN protein level was assessed in SK-N-BE(2)-C. C Cell morphology was
observed via brightfield microscope. All the experiments were performed in triplicates and a representative result or mean is shown; error
bars show standard deviation.
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and polyamines has not been widely studied, it appears that
polyamine production is increased upon PI3K activation [34].
Additionally, in prostate cancer mTORC1 has been recently shown
to activate polyamine synthesis through the regulation of the
enzymes involved in polyamine production [35]. mTORC1 can
elevate polyamine levels by increasing ODC1 mRNA stability, and
it also blocks antizyme production [36, 37]. We show that
verlindamycin, as a polyamine analog, decreases polyamine levels
and induces antizyme production leading also to a downregula-
tion of PI3K-mTOR pathway in neuroblastoma.
Previously, verlindamycin has been mostly studied as an LSD1
inhibitor, not polyamine analog. The compound was selected in a
library screen as the biguanide most efficiently inhibited the
enzymatic activity of LSD1 [11]. Verlindamycin was shown to re-
activate expression of aberrantly silenced genes in colon cancer,
breast cancer, and AML cell lines [11–13]. We previously
demonstrated that LSD1 inhibition with tranylcypromine reacti-
vates ATRA-induced differentiation in AML, which then led to a
promising clinical trial [14, 38]. MYCN directly interacts with LSD1
and inhibition of both MYCN and LSD1 was shown to be an
efficient strategy for inhibition of neuroblastoma cell prolifera-
tion [39]. This may be why verlindamycin proved to be so
efficient in neuroblastoma—it is a single molecule able to inhibit
LSD1 and downregulate MYCN. However, because the effect of
verlindamycin was not recapitulated by neither chemical nor
genetic LSD1 inhibitor, we suggest that LSD1 blockade is not
enough to enhance the differentiation-inducing potential of
ATRA in neuroblastoma.
In conclusion, we hereby present this novel inhibitory mechan-
ism of verlindamycin as a potential therapeutic treatment of
neuroblastoma, including MYCN-amplified high-risk subgroup, for
the first time.
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